REFERENCES
1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
3. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler2010; 16: 1443-1452.
4. Uzawa A, Mori M, Masuda S, Muto M and Kuwabara S. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2013; 84: 517-522.
5. Uzawa A, Mori M and Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications.Brain Pathol 2014; 24: 67-73.
6. Khaibullin T, Ivanova V, Martynova E, et al. Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients. Front Immunol 2017; 8: 531.
7. Michael BD, Elsone L, Griffiths MJ, et al. Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms - a pilot study. Cytokine 2013; 64: 90-96.
8. Wang KC, Lee CL, Chen SY, et al. Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis. J Interferon Cytokine Res 2013; 33: 58-64.
9. Harris HE and Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006; 7: 774-778.
10. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-2660.
11. Uzawa A, Mori M, Taniguchi J, Masuda S, Muto M and Kuwabara S. Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol 2013; 172: 37-43.
12. Shichita T, Hasegawa E, Kimura A, et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain.Nat Med 2012; 18: 911-917.
13. Yun HM, Park KR, Kim EC and Hong JT. PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption. Oncotarget 2015; 6: 20875-20884.
14. Masuda H, Mori M, Uchida T, Uzawa A, Ohtani R and Kuwabara S. Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. J Neuroimmunol 2017; 305: 102-107.
15. Sugimoto K, Mori M, Liu J, et al. The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. J Neuroimmunol 2019; 336: 577021.
16. Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T and Kuwabara S. Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. Clin Exp Immunol 2018; 193: 47-54.
17. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573.
18. Holley JE, Newcombe J, Winyard PG and Gutowski NJ. Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes. Mult Scler 2007; 13: 955-961.
19. Voigt D, Scheidt U, Derfuss T, Brück W and Junker A. Expression of the antioxidative enzyme peroxiredoxin 2 in multiple sclerosis lesions in relation to inflammation. Int J Mol Sci 2017; 18: 760.